Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
32466
CAS Number:
6190-39-2
Sal de metanosulfonato de dihidroergotamina
Purity:
≥ 99 % (HPLC)
Synonym(s):
Mesilato de dihidroergotamina
Documents
$88.63 /100 mg
Tamaño
Request Bulk Quote
Información del producto

Agonista de los receptores de serotonina vasculares; agonista parcial de los receptores alfa-adrenérgicos y dopaminérgicos D2. Mantener el envase bien cerrado en un lugar seco y bien ventilado.

Número CAS
6190-39-2
Fórmula molecular
C33H37N5O5 · CH4O3S
Peso molecular
679.78
Número MDL
MFCD00058615
Punto de fusión
230 - 235 °C
Rotación óptica
[a] D 20 = -17 a -23 ° (C = 0,25, método JP) (calculado sobre sustancia seca)
Condiciones
Tienda en RT
Información general
Número CAS
6190-39-2
Fórmula molecular
C33H37N5O5 · CH4O3S
Peso molecular
679.78
Número MDL
MFCD00058615
Punto de fusión
230 - 235 °C
Rotación óptica
[a] D 20 = -17 a -23 ° (C = 0,25, método JP) (calculado sobre sustancia seca)
Condiciones
Tienda en RT
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Dihydroergotamine methanesulfonate salt is widely utilized in research focused on:

  • Migraine Treatment: This compound is primarily used in the medical field to treat acute migraine attacks. It works by constricting blood vessels in the brain, providing relief to patients who suffer from severe headaches.
  • Vascular Research: In pharmacological studies, it serves as a model compound for understanding vascular responses. Researchers can explore its effects on blood flow and vascular tone, aiding in the development of new cardiovascular therapies.
  • Pharmaceutical Development: The compound is often used in the formulation of medications, allowing scientists to study its stability and efficacy in various delivery systems, such as intranasal or injectable forms.
  • Neuropharmacology: It is utilized in neuropharmacological research to investigate its interactions with serotonin receptors, contributing to the understanding of neurotransmitter systems and potential treatments for other neurological disorders.
  • Clinical Trials: Dihydroergotamine methanesulfonate salt is frequently involved in clinical trials aimed at assessing new therapeutic strategies for migraine and other headache disorders, providing valuable data for future drug approvals.

Citas